We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

6886:HKEXHuatai Securities Co., Ltd. Class H Analysis

Data as of 2026-06-21 - not real-time

CN¥30.40

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Anhui Wanyi Science and Technology is trading at CNY 30.4, comfortably above its 20‑day (27.02), 50‑day (27.47) and 200‑day (25.20) simple moving averages, indicating a strong upward bias. The RSI of 66.6 and a bullish MACD histogram (+0.39) suggest momentum is still positive, though the RSI hints at a potential overbought condition. Valuation metrics are stretched: the trailing P/E of 52.4 far exceeds the industry average of 38.1, and the DCF‑derived fair value of just CNY 4.30 implies a massive discount to the current price. Revenue is expanding rapidly at 33.5% year‑over‑year, supported by a solid gross margin of 47% and a modest operating margin of 7.7%, while cash balances (CNY 244 m) dwarf total debt (CNY 48 m), making the dividend of 0.66% sustainable. Volatility is high at 51.6% over the past 30 days, yet beta remains low at 0.30, indicating limited systematic risk. Analyst consensus is thin, with a single target price of CNY 29.63, slightly below market, and the Fear & Greed Index at 91.5 (Extreme Greed), signaling potential complacency among investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near resistance at CNY 31.76
  • RSI indicating possible overbought
  • Bullish MACD supporting short‑term momentum

Medium Term

1–3 years
Cautious
Model confidence: 6/10

Key Factors

  • Significant valuation gap (P/E 52.4 vs industry 38.1)
  • DCF fair value far below market price
  • Analyst target price below current level

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth and cash generation
  • Sustainable dividend with low payout ratio
  • Low systematic risk (beta 0.30) despite high volatility

Key Metrics & Analysis

Financial Health

Revenue Growth33.50%
Profit Margin9.67%
P/E Ratio52.4
ROE9.43%
ROA2.62%
Debt/Equity6.04
P/B Ratio4.7
Op. Cash FlowCN¥146.4M
Free Cash FlowCN¥10.6M
Industry P/E38.1

Technical Analysis

TrendNeutral
RSI66.6
SupportCN¥25.32
ResistanceCN¥31.76
MA 20CN¥27.02
MA 50CN¥27.47
MA 200CN¥25.20
MACDBullish
VolumeStable
Fear & Greed Index91.46

Valuation

Fair ValueCN¥4.30
Target PriceCN¥29.63
Upside/Downside-2.55%
GradeOvervalued
TypeGrowth
Dividend Yield0.66%

Risk Assessment

Beta0.30
Volatility51.65%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.